Results 121 to 130 of about 2,330 (177)

Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment. [PDF]

J Patient Rep Outcomes
Buniotto F, Tridello G, De Scolari A, Meneghelli I, Pintani E, Perobelli S, Cipolli M.   +6 more
europepmc   +1 more source

Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Kogias C, Sopiadou A, Fouzas S, Vantsi P, Chrysochoou EA, Desli E, Galogavrou M, Gasparis N, Hatziagorou E.   +8 more
europepmc   +1 more source

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis.

Australian prescriber
openaire   +1 more source

Long-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor on Nocturnal Cardiorespiratory Polygraphy Parameters in Patients with Cystic Fibrosis: A Prospective Study. [PDF]

Life (Basel)
Tosto M, Parisi GF, Presti S, Papale M, Pecora G, Mulè E, Ornato V, Aloisio D, Manti S, Leonardi S.   +9 more
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Muscle Composition in Cystic Fibrosis: An AI-Assisted Chest CT-Based Body Composition Analysis. [PDF]

Med Sci (Basel)
Welsner M, Stehling F, Gruber W, Westhölter D, Sutharsan S, Taube C, Büscher E, Nensa F, Zensen S, Umutlu L, Forsting M, Haubold J, Salhöfer L, Holtkamp M, Kohnke J, Hosch R, Opitz M.   +16 more
europepmc   +1 more source

Systemic and airway T cell dynamics with influenza-specific immune recovery by cystic fibrosis elexacaftor/tezacaftor/ivacaftor therapy. [PDF]

Respir Res
Mouchtaridi E, Kowalik A, Raineri EJM, Humbert M, Jägerstedt J, Bojarlind M, Nilsson K, Flodström-Tullberg M, Pincikova T, Sandberg JK.   +9 more
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor Supports Treatment for CF with ΔI1023-V1024-CFTR. [PDF]

Int J Mol Sci
Huang Y, Gonzales Cordova JM, Penrod S, Bendy LL, Cheng PC, Sanders DB, Davis MD, Gaston B, Chmiel JF.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy

Archives of Gynecology and Obstetrics, 2023
Management of cystic fibrosis has recently stepped forward with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, although data on potential adverse effects are lacking for many categories of patients, such as pregnant women.We report one of the first reports on the outcome of pregnancy in a woman treated with ...
Giuseppe Cimino, Sara Sorrenti, Manuel Murciano, Paola Galoppi, Fiorentina Ascenzioni, Bruno Botta, Roberto Brunelli, Luca Cavinato, Andrea Cerrato, Gabriele Cianfoni, Valentina D’Ambrosio, Francesca De Luca, Paola Delporto, Maria Di Chiara, Paola Galoppi, Francesco Gasparrini, Francesca Ghirga, Antonella Giancotti, Aldo Laganà, Giulia Mazzoccanti, Alessandro Mondo, Carmela Maria Montone, Manuel Murciano, Francesco Pecorini, Maria Grazia Piccioni, Damiana Pompeo, Lorenzo Spiniello, Gianluca Terrin, Patrizia Troiani, Fabrizio Zullo   +29 more
openaire   +3 more sources

Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events

American Journal of Respiratory and Critical Care Medicine
Abstract Rationale Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and efficacious in people with cystic fibrosis (pwCF) aged 2 years and older with at least one F508del-CFTR allele or more. After U.S.
Bonnie Ramsey, David R Demaso, Edward Mckone   +2 more
exaly   +3 more sources

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis

Therapeutic Advances in Respiratory Disease, 2022
Background: Cystic fibrosis (CF) is associated with worsening of depression and anxiety symptoms. Elexacaftor/tezacaftor/ivacaftor (Trikafta®), a cystic fibrosis transmembrane regulator (CFTR) modulator approved in 2019, significantly improves lung function, decreases pulmonary exacerbations, and improves ...
Lijia Zhang, Dana Albon, Marieke K Jones   +2 more
exaly   +4 more sources